Search

Your search keyword '"Aly, Karsan"' showing total 8 results
Start Over Author "Aly, Karsan" Journal journal of thoracic oncology
8 results on '"Aly, Karsan"'

2. P1.01-40 EGFR ctDNA Detection: The Impact of Site of Progression and Burden of Progressive Disease

Author

C. Hughesman, E. Law, Tracy Tucker, Amadea Kristanti, Stephen Yip, Aly Karsan, Cheryl Ho, Alexandra Pender, Kelly McNeil, Sean S. Young, Ian Bosdet, and Janessa Laskin

Subjects
Pulmonary and Respiratory Medicine, Oncology, medicine.medical_specialty, business.industry, Internal medicine, Medicine, business, medicine.disease, Progressive disease
Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results

3. P3.01-049 ELF3 Overexpression Leads to Oncogenic Reprogramming of Protein Interactions Exposing Therapeutically Actionable Targets

Author

Calum MacAulay, Kevin W. Ng, Katey S. S. Enfield, Aly Karsan, Daiana D. Becker-Santos, Stephen Lam, Christine Anderson, William W. Lockwood, Erin A. Marshall, Wan L. Lam, Sara Rahmati, Katerina Politi, Jennifer Kennett, Raj Chari, Megan Fuller, Igor Jurisica, and David A. Rowbotham more...

Subjects
Pulmonary and Respiratory Medicine, Oncology, medicine, Cancer research, Biology, Lung cancer, medicine.disease, Reprogramming, Protein–protein interaction
Published
2017
Full Text
View/download PDF

4. P3.01-019 Canadian Multicenter Validation Study of Plasma Circulating Tumor DNA for Epidermal Growth Factor (EGFR) T790M Testing

Author

Iyare Izevbaye, Natasha B. Leighl, Suzanne Kamel-Reid, Tristan A. Barnes, M. Iqbal, Parneet Cheema, Ronald Burkes, Tong Zhang, J. Rothenstein, G. Liu, Janessa Laskin, Aly Karsan, Léon C van Kempen, M. Tsao, S. Owen, and Alan Spatz more...

Subjects
Pulmonary and Respiratory Medicine, Validation study, Oncology, Epidermal growth factor, business.industry, Circulating tumor DNA, Immunology, Cancer research, Medicine, EGFR T790M, business
Published
2017
Full Text
View/download PDF

5. OA 07.07 Inhibition of the Novel Oncogene ELF3 Abolishes Lung Adenocarcinoma Growth

Author

Stephen Lam, Kevin W. Ng, William W. Lockwood, Calum MacAulay, Christine Anderson, Aly Karsan, Wah-Kit Lam, Sara Rahmati, Igor Jurisica, Erin A. Marshall, and K. Enfield

Subjects
Pulmonary and Respiratory Medicine, Oncology, medicine.medical_specialty, Lung, medicine.anatomical_structure, Oncogene, business.industry, Internal medicine, medicine, Adenocarcinoma, business, medicine.disease
Published
2017
Full Text
View/download PDF

6. P1.02-011 Comparison of EGFR and KRAS Mutations in Archival Tissue and Circulating Tumor DNA: The Impact of Tumor Heterogeneity

Author

Cheryl Ho, Hagen F. Kennecke, Lucas Swanson, Ian Bosdet, Aly Karsan, Kevin Bushell, Ying Wang, Barbara Melosky, Janessa Laskin, Solomon A. Vandt, Sophie Sun, Ryan D. Morin, and Nevin Murray

Subjects
Pulmonary and Respiratory Medicine, Oncology, medicine.medical_specialty, business.industry, medicine.disease_cause, Tumor heterogeneity, Circulating tumor DNA, Internal medicine, Archival tissue, Medicine, KRAS, business, Gene
Published
2017
Full Text
View/download PDF

7. Canadian Anaplastic Lymphoma Kinase Study: A Model for Multicenter Standardization and Optimization of ALK Testing in Lung Cancer

Author

Richard S. Fraser, Iyare Izevbaye, Jean Deschenes, Joan H.M. Knoll, Ronald F. Carter, Martin J. Trotter, Wenda Greer, Fariborz Rashid-Kolvear, Josee Lavoie, Miriam Blumenkrantz, Jie Xu, David M. Hwang, Jean-Claude Cutz, Danh Tran-Thanh, Harmanjatinder S. Sekhon, Flechere Fortin, Guilherme Brandao, Janette A. van den Berghe, Emina Torlakovic, Melania Pintilie, Sungmi Jung, Rania Gaspo, Ming-Sound Tsao, Yasushi Yatabe, Gilbert Bigras, Roula Albadine, Diana N. Ionescu, Anna Bojarski, Christian Couture, Aly Karsan, Zhaolin Xu, Kenneth J. Craddock, A. John Iafrate, Ben J. Blencowe, Isabelle Gorska, and Gilbert B. Côté more...

Subjects
Male, Pulmonary and Respiratory Medicine, Canada, Pathology, medicine.medical_specialty, Lung Neoplasms, Diagnostic methods, reverse-transcriptase polymerase chain reaction, medicine.drug_class, Adenocarcinoma of Lung, Adenocarcinoma, hemic and lymphatic diseases, Humans, Anaplastic lymphoma kinase, Medicine, Anaplastic Lymphoma Kinase, Prospective Studies, Lung cancer, Prospective cohort study, In Situ Hybridization, Fluorescence, medicine.diagnostic_test, Reverse Transcriptase Polymerase Chain Reaction, business.industry, Fluorescence in situ hybridization, Receptor Protein-Tyrosine Kinases, Reproducibility of Results, DNA, Neoplasm, Middle Aged, medicine.disease, Immunohistochemistry, Standardization, ALK inhibitor, Oncology, Female, ALK testing, business, Follow-Up Studies, Blinded study
Abstract

Introduction Fluorescence in situ hybridization (FISH) is currently the standard for diagnosing anaplastic lymphoma kinase (ALK)-rearranged (ALK+) lung cancers for ALK inhibitor therapies. ALK immunohistochemistry (IHC) may serve as a screening and alternative diagnostic method. The Canadian ALK (CALK) study was initiated to implement a multicenter optimization and standardization of laboratory developed ALK IHC and FISH tests across 14 hospitals. Methods Twenty-eight lung adenocarcinomas with known ALK status were used as blinded study samples. Thirteen laboratories performed IHC using locally developed staining protocols for 5A4, ALK1, or D5F3 antibodies; results were assessed by H-score. Twelve centers conducted FISH using protocols based on Vysis' ALK break-apart FISH kit. Initial IHC results were used to optimize local IHC protocols, followed by a repeat IHC study to assess the results of standardization. Three laboratories conducted a prospective parallel IHC and FISH analysis on 411 consecutive clinical samples using post-validation optimized assays. Results Among study samples, FISH demonstrated 22 consensus ALK+ and six ALK wild type tumors. Preoptimization IHC scores from 12 centers with 5A4 and the percent abnormal cells by FISH from 12 centers showed intraclass correlation coefficients of 0.83 and 0.68, respectively. IHC optimization improved the intraclass correlation coefficients to 0.94. Factors affecting FISH scoring and outliers were identified. Post-optimization concurrent IHC/FISH testing in 373 informative cases revealed 100% sensitivity and specificity for IHC versus FISH. Conclusions Multicenter standardization study may accelerate the implementation of ALK testing protocols across a country/region. Our data support the use of an appropriately validated IHC assay to screen for ALK+ lung cancers. more...

Full Text
View/download PDF

8. ELF3 amplification at 1q32.1 promotes SMAD4-independent tumorigenesis

Author

Wan L. Lam, Katey S. S. Enfield, Kevin W. Ng, Megan Fuller, Brenda C. Minatel, Christine Anderson, Katy Milne, Erin A. Marshall, David A. Rowbotham, Raj Chari, Aly Karsan, Daiana D. Becker-Santos, Stephen Lam, and Calum MacAulay more...

Subjects
Pulmonary and Respiratory Medicine, Oncology, business.industry, Cancer research, Medicine, business, Carcinogenesis, medicine.disease_cause
Full Text
View/download PDF